Spexin mRNA and protein are widely expressed in rat tissues and associate with weight loss in rodents of diet-induced obesity. Its location in endocrine and epithelial cells has also been suggested. Spexin is a novel peptide that involves weight loss in rodents of diet-induced obesity. Therefore, we aimed to examine its expression in human tissues and test whether spexin could have a role in glucose and lipid metabolism in type 2 diabetes mellitus (T2DM). The expression of the spexin gene and immunoreactivity in the adrenal gland, skin, stomach, small intestine, liver, thyroid, pancreatic islets, visceral fat, lung, colon, and kidney was higher than that in the muscle and connective tissue. Immunoreactive serum spexin levels were reduced in T2DM patients and correlated with fasting blood glucose (FBG, r = −0.686, P < 0.001), hemoglobin A1c (HbA1c, r = −0.632, P < 0.001), triglyceride (TG, r = −0.236, P < 0.001) and low density lipoprotein-cholesterol (LDL-C, r = −0.382, P < 0.001). A negative correlation of blood glucose with spexin was observed during oral glucose tolerance test (OGTT). Spexin is intensely expressed in normal human endocrine and epithelial tissues, indicating that spexin may be involved in physiological functions of endocrine and in several other tissues. Circulating spexin levels are low in T2DM patients and negatively related to blood glucose and lipids suggesting that the peptide may play a role in glucose and lipid metabolism in T2DM.
Introduction
Spexin is a peptide that was identified through modern bioinformatics search strategies [1, 2] . In humans, spexin is a product of the Ch12orf39 gene. The prepropeptide is composed of 116 amino acid residues (GeneBank database XM 001076968) Mature spexin contains 14 amino acids. Rat spexin differs from the human and mouse peptide sequences by one amino acid within the C-terminal portion, ending with the sequence GHR instead of GRR [2] .
Previous studies have revealed the widespread expression of spexin mRNA and protein in rat tissues including the hypothalamus, cerebral cortex, hippocampus, pons, retina, esophagus, stomach, kidney, ovary, and adrenal gland [3] . Its location in endocrine cells and its ability to be secreted suggest its possible role as an endocrine factor. Moreover, an important role of spexin in the functioning of epithelial cells has also been suggested [3] . However, the expression of spexin mRNA and protein in human tissues is unknown. In this study, we examined its expression in human tissues, particularly endocrine and epithelial tissues.
Little is known about the functions of spexin. The synthetic amidated spexin peptide NWTPQAMLYLKGAQ-amide has been found to induce muscle contraction in a dose-dependent manner in a stomach explant contractility assay [1] . Recent studies have demonstrated that spexin reduces the rate of adrenocortical cell proliferation and may evoke an increase in aldosterone and glucocorticoid secretion in some rat adrenocortical cell cultures and modulate cardiovascular and renal functions and nociception [4, 5] . Treatment of goldfish with spexin decreased the secretion of luteinizing hormone and suppressed appetite [6, 7] . Despite accumulating evidence for physiological roles of spexin, other functions of spexin have not yet been demonstrated. Identification of the tissue or cell types that express spexin in humans would contribute to clarifying its physiological function, especially in type 2 diabetes mellitus (T2DM).
T2DM is associated with disturbances in glucose and lipid metabolism usually caused by sedentary life style and increased food consumption. Recent studies have shown a relationship between spexin and body weight regulation [7, 8] . In particular, spexin gene expression is markedly down-regulated in obese human fat. The peptide produces weight loss in rodent models of diet-induced obesity. These findings suggest that spexin might be related to glucose homeostasis and lipid metabolism in T2DM. In this study we wanted to examine spexin localization in human tissues and circulating spexin levels after glucose load in T2DM patients.
Materials and methods

Human samples
Three to four samples of normal adult human thyroid, pancreas, adrenal gland, visceral fat, skin, small intestine, colon, stomach, liver, lung, kidney, skeletal muscle, myometrium and bladder smooth muscle were obtained from surgical human specimens in the Department of Pathology at Shanghai General Hospital affiliated to Shanghai Jiao Tong University School. 38 subjects (20 males and 18 females aged 28-72 y) were examined. For real-time PCR studies, the tissues (approximately 0.5 cm 3 ) were immediately stored in liquid nitrogen. Tissues (approximately 0.5 cm 3 ) for immunohistochemical staining were fixed in 10% buffered formalin for 48 h and paraffin embedded.
Next we enrolled 121 subjects with T2DM and 105 healthy individuals participated in the study as control subjects. None of the healthy volunteers were taking any medication, and none had a first-degree relative with T2DM. Those with hypertension, acute or chronic infectious disease, autoimmune diseases, heart failure, hepatic disease, or renal disease were excluded. Blood samples were collected at rest at 8:00 A.M., after an overnight fast and 24 h alcohol abstention. Serum was separated into vials and stored at −80 • C.
We also enrolled 12 healthy volunteers (aged: 52.8 ± 9.2 years with BMI: 23.3 ± 1.8 kg/m 2 ) including 5 males and 7 females in our study. None were taking any medication affecting glucose tolerance (␤-blockers, thiazide diuretics, and corticoids) and none had a first degree relative with T2DM. Oral glucose tolerance test (OGTT) was performed using the International Expert Committee criteria [9] .
The study was approved by the Institutional Review Board of Shanghai General Hospital affiliated to Shanghai Jiao Tong University School of Medicine (diary code, 2014KY094) and was performed in accordance with the principle of the Helsinki Declaration.
Conventional RT-PCR and quantitative real-time PCR
PCRs were performed using the methods as previously described [3, [10] [11] [12] . Briefly, total RNA was extracted using TRIzol Reagent (Invitrogen; Carlsbad, CA, USA); mRNA was extracted from the total RNA using the PolyATtract mRNA Isolation System III (Promega; Madison, WI, USA). RT was performed using AMV Reverse Transcriptase with Oligo dT as primers (Promega; Madison, WI, USA). The primers used were designed by Primer 5 software (Whitehead Institute for Biomedical Research; Cambridge, MA, USA). The primer sequences for Spexin were 5 -GAGGCAGCAAC-CATCTTA -3 (forward) and 5 -TTCACCAGTTAAGCAGACT-3 (reverse). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control, and its primers were as follows: 5 -ATGGGGAAGGTGAAGGTCG-3 (forward) and 5 -GGGGT-CATTGATGGCAACAATA -3 (reverse). For all of the tested genes, 35 cycles of the following sequences were applied: denaturation, 94 • C for 30 s; annealing, 60 • C for 60 s; and extension, 68 • C for 60 s. The reaction products were separated on 2% agarose gels containing ethidium bromide and photographed with a transilluminator.
Quantitative real-time PCR (qRT-PCR) was performed by means of Applied Biosystems ViiA TM 7 (Life Technologies; Burlington, ON, USA). The SYBR green detection system was used with the above-mentioned primers, which were also used for conventional RT-PCR. Each of the 20 l reaction mixtures contained 2 l of template cDNA (or standards or control), 0.8 l of each gene-specific primer (2.5 mol/L), 0.4 l ROX Reference Dye II and 10 l 2 × SYB Green Premix Ex TaqTM (Takara; Tokyo, Japan). The real-time PCR program included a 10-min denaturation step to activate the TaqDNA polymerase, followed by a three-step amplification program (denaturation at 95 • C for 10 s, annealing at 60 • C for 5 s, and extension at 72 • C for 10 s). At the end of the reaction process, the dissociation curve was derived by heating the amplicon from 60 to 95 • C. All qRT-PCRs were run in both technical and biological triplicates. The specificity of the reaction products was checked by determining their melting points (0.1 • C/sec transition rate). PCR efficiency was calculated by converting the slope produced by the linear regression of the curves to percentage efficiency using the formula: Efficiency = −1 + 10(−1/slope) as previously described [13] . The obtained results were normalized to GAPDH, which was used as a reference gene. Data was analyzed using the 2 (−delta deltaCt) methods as previously described [14] . Relative spexin expression is calculated relative to the expression of spexin in skeletal muscle.
Immunohistochemistry
Immunohistochemical analysis was performed as previously described [15, 16] . Sections of human samples were hydrated gradually through decreasing concentrations of ethanol and then washed in deionized H 2 O. They were incubated in 0.3% hydrogen peroxide for 10 min at room temperature to quench endogenous peroxidase activity and then in blocking serum (2% normal goat serum) for 30 min. The sections of human samples were incubated with primary rabbit polyclonal antibody recognizing spexin and pro/prepro-peptide (H-023-81; Phoenix Pharmaceuticals, Burlingame, CA, USA) diluted 1:200 in PBS for 1 h at room temperature. The sections of human samples were then washed three times for 5 min each in PBS, incubated with anti-rabbit serum for 30 min (catalog no. MP-7500; Vector Laboratories, Burlingame, CA, USA), and then developed in DAB (Sigma-Aldrich; Milan, Italy). Finally, the sections were counterstained with hematoxylin. Negative controls were performed by the omission of the primary antibody. Spexin immunoreactivity detected in human stomach was used as a positive control, as suggested in the datasheet of the antibody. To verify the immunohistochemical specificity of the reaction, absorption tests with spexin (No.023-81; Phoenix Pharmaceuticals) were also performed.
Immunohistochemical staining for spexin was evaluated by scanning entire tissue specimens under low power magnification (5×) and later confirmed under high power magnifications (10×, 20×, and 40×). Immunohistochemical evaluation included the number of positive cells and staining intensity. Overall staining area and intensity was stratified as follows: −, negative; ±, barely detectable; +, weak; + +, moderate; and + + +, strong [15] . Image-Pro plus 6 software was used to quantify the integrated optical density (IOD).
Anthropometric, biochemical measurements and spexin immunoassay
All subjects were assessed after overnight fasting. Body weight, height, systolic pressure (SBP), and diastolic pressure (DBP) were measured by an experienced physician. BMI was calculated as weight in kilograms divided by height in meters squared. Fasting blood glucose (FBG), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured using an autoanalyser (Beckman, CA, USA). Plasma glucose concentrations were measured using the oxidase method. Hemoglobin A1c (HbA1c) was evaluated by a high performance liquid chromatography technique (HPLC VariantTM, Bio-Rad, Germany). Spexin was analyzed by an enzyme-linked immunosorbent assay (CSB-EL003071HU, CUSABIO, Wuhan, China). All measurements were performed in duplicate, and the mean of the two measurements was considered. The linear range of the assay was 0.0625 −4 ng/ml.
Statistical analysis
Statistical analysis was performed using the SPSS statistical software for Windows (Version 20.0). Numerical data are presented as mean ± SD. Skewed distributed data were logarithmically transformed before analysis. Comparisons between groups were carried out using independent-samples t test or paired-samples t test or one-way ANOVA. To analyze the categorical data, a chi-square test was used and descriptive statistics are presented as frequency (%). Correlation analyses adjusted by age, gender and body weight were performed using Pearson's test or Partial's test. The P values below 0.05 were considered statistically significant.
Results
Spexin is intensely expressed by gene and immunohistochemistry in most endocrine tissues, especially the adrenal gland
Spexin gene was detected in most of the endocrine tissues we studied, with an at least 10-fold higher expression in human adrenal gland than in skeletal muscle (Fig. 1A and B) . In the thyroid, pancreas, and visceral fat, the mRNA level of spexin was approximately 5-10-fold higher than that in skeletal muscle (Fig 1A, B) . Further immunohistochemical detection of spexin protein confirmed the high expression of spexin (Table 1) . We found widespread spexin immunostaining in human thyroid, adrenal gland, pancreatic islets and visceral fat, although its expression levels differed among cell populations (Fig 1C) . Spexin was located primarily in the cytoplasm (See Supplementary file S1).
In the thyroid, follicular epithelial cells showed heterogeneous staining. The epithelial cells showed moderate cytoplasmic staining in some follicles, and no immunostaining in others. Both the adrenal cortex cells and medullary cells showed intense cytoplasmic spexin immunostaining. The cells of the islets of Langerhans showed high spexin immunoreactivity. Visceral fat cells showed moderate spexin immunoreactivity. The IOD of spexin staining in pancreatic islets, thyroid, adrenal gland, and visceral fat were 231,915 ± 19687, 56,396 ± 7287, 521,669 ± 28925, and 97,717 ± 12126, respectively. They were significantly higher than that in skeletal muscle (21,541 ± 1500).
Spexin is abundant in the epithelia and glands of the main human organs and tissues
Spexin gene expressions in the skin, stomach, small intestine, and liver were at least 10-fold higher than that in skeletal muscle (Fig 2) . The gene expressions of spexin in the colon, lung, and kidney were 5-10-fold higher than that in skeletal muscle. Immunohistochemical localization of spexin was observed in the epithelia and glands of most of the examined organs (particularly in the skin, stomach, small intestine, colon, lung, and renal tubules) and was exclusively cytoplasmic (Table 1, Fig 3) . Along the alimentary canal, spexin cytoplasmic immunoreactivity was also identified in the ganglionic cells of the submucosal and muscle plexuses. The connective tissue structures (lamina propria and submucosal layer) showed negative staining while the muscle layers showed weak/moderate staining. Most of the glandular epithelial cells in the stomach showed intense cytoplasmic immunostaining. The immunoreactivity at the base of the gastric glands was more abundant. The epithelial cells in the small intestine showed high cytoplasmic immunostaining, whereas the crypt cells showed less intense. The epithelial cells in the colon showed moderate/strong cytoplasmic staining, whereas the mucus droplets of goblet cells showed negative staining. Hepatocytes showed intense cytoplasmic staining without nuclear immunoreactivity. The bronchiolar epithelial cells and alveolar epithelium cells exhibited moderate cytoplasmic staining. No staining was observed in the tracheal or bronchial cartilage. The renal corpuscles were negative for staining. Positive cytoplasmic immunoreactivity was observed only in the epithelium of the loop of Henle and the distal tubules. Regarding the exocrine pancreas, the great majority of acinar secretory cells were negative, although rare acinar secretory cells with weak cytoplasmic immunoreactivity were found. The IOD of spexin staining in the lung, kidney, skin, small intestine, liver, colon, and stomach were 84,670 ± 11318, 342,897 ± 33830, 187,708 ± 30382, 174,502 ± 17196, 614,126 ± 17871, 159,947 ± 17447, and 229,091 ± 17196, respectively. They were significantly higher than that in the skeletal muscle (21,541 ± 1500).
Spexin expression is very weak in human muscle and connective tissues
As shown in Fig. 4A and B, spexin gene expression was very low in the skeletal muscle, connective tissue, and smooth muscle (uterus and bladder). Accordingly, skeletal muscle cells and smooth muscle cells (uterus and bladder) showed weak immunostaining, and connective tissue was negative for spexin immunoreactivity (Fig 4C) .
Serum spexin Levels are lower in T2DM and significantly correlated with glucose and lipid levels
Clinical and biochemical characteristics of the study subjects were shown in Table 2 . Serum levels of spexin were significantly lower in T2DM (2.04 ± 0.70 ng/mL versus 3.65 ± 0.73 ng/mL, Data are presented as number (percentage) for categorical data and mean ± SD for continuous data. Quantitative PCR analysis of spexin expression in human epithelial and other tissues. The results were normalized using GAPDH as a reference gene. P = 0.000). Furthermore, correlations between serum spexin levels and FBG (r = −0.686, P < 0.001), HbA1c (r = −0.632, P < 0.001) was observed. And correlations between serum spexin levels and TG (r = −0.236, P < 0.001), LDL-C (r = 0.382, P < 0.001) also remained significant. Spexin levels are associated with those of glucose and lipids.
3.5. A negative correlation of blood glucose with spexin was observed during the OGTT During the OGTT, spexin exhibited a progressive and significant decrease from time 0 to 60 min (P < 0.05) and returned gradually to the basal values at 180 min. A negative correlation of blood glucose values with spexin values was observed during the OGTT (Table 3 ).
Discussion
Porzionato et al. [3, 17] studied spexin expression in normal rat tissues and found that spexin was highly expressed in endocrine cells and epithelial cells in normal rat tissues. As such, we studied spexin expression in endocrine cells and epithelial cells in human normal tissues. To our knowledge, the present study is the first in the literature that evaluates spexin expression in the epithelial, muscle, endocrine, and numerous other organs in normal humans. Spexin gene expression and immunohistochemical localization detecting spexin and pro/prepro-peptide were consistent in thyroid, adrenal gland, visceral fat, skin, small intestine, colon, stomach, liver, lung, skeletal muscle, smooth muscle and connective tissue. But some small discrepancies were found in terms of the levels of expression in pancreas and kidney. This may be primarily due to post-transcriptional regulatory mechanisms of protein synthesis.
In general, the spexin immunoreactivity in the epithelial cells of the entire digestive system, respiratory conducting airways, kidney, and skin were very intense. The highest level of spexin expression in both simple and stratified epithelia suggests its involvement in transepithelial transport (including secretion) and may also be connected with the regulation of the rate of epithelial cell renewal. All epithelia are characterized by a high proliferation rate, and we cannot exclude the role of spexin in the modulation of proliferation, differentiation, and death of cells in both surface and glandular epithelia [3] . In particular, spexin immunostaining was negative or weak in connective tissue, skeletal muscle and smooth muscle.
Our study revealed spexin expression in all of the endocrine glands studied and highest levels of expression in adrenal gland, which is in accordance with the previous findings that the highest levels of spexin mRNA was present in adult rat adrenal glands. Rucinski et al. [4] found that prolonged ACTH administration decreased and dexamethasone increased adrenal spexin mRNA levels in vivo. The results also suggest the direct involvement of spexin in the regulation of adrenocortical cell proliferation. Wong et al. [7] found that spexin mRNA levels in the telencephalon, optic tectum, and hypothalamus of goldfish brain could be elevated by food intake. Additionally, the injection of spexin into the goldfish brain inhibited both basal and orexin-induced feeding behavior and food consumption. Furthermore, the researchers also found that spexin gene expression was markedly down-regulated in obese human fat tissue. Spexin is a potent, natural satiety-inducing peptide that plays a key role in regulating feeding behavior, uptake of long-chain fatty acids into adipocytes, energy utilization and metabolism, and body weight. In diet-induced obesity rats, spexin (35 g/kg/day by intraperitoneal injection daily for 19 days) reduced caloric intake ∼32% with corresponding weight loss (y = −0.0666 × + 38.3, r = −0.7318). Spexin is a novel hormone involved in weight regulation, with the potential for being targeted in obesity therapy [8] .
Of special interest is the distribution of spexin immunoreactivity in the islets of the pancreas of normal human beings. We found that spexin is highly expressed in the islets of the pancreas of normal human beings, which is quite different from its expression in the pancreatic islets of rats [3] . Syntenic analysis and relocating spexin and their neighbor genes on reconstructed vertebrate ancestral chromosomes reveal that spexin resides in the near vicinity of the kisspeptin and galanin gene families on the chromosomes [18] . Furthermore, a ligand-receptor interaction study shows that spexin activate human, Xenopus, and zebra fish GALR2/3 family receptors, suggesting that spexin is natural ligand for galanin 2/3. A positive correlation of galanin with T2DM and metabolic syndrome has been previously reported [19] [20] [21] [22] . Endogenous galanin reduces insulin resistance by increasing GLUT4 content and promoting GLUT4 transportation from the intracellular membranes to the plasma membranes in adipocytes [23] . These results suggest that spexin may have some relationship with T2DM. Therefore we examined the correlations between serum spexin and blood glucose and lipid in patients with T2DM. Our data showed that serum spexin levels were significantly lower in T2DM as compared with the lean controls. Meanwhile, a negative correlation of blood glucose with spexin was observed during the time scale of OGTT. Significant correlations between spexin and blood glucose and lipids suggest that the peptide may play an important role in glucose and lipid metabolism in T2DM. In summary, this study confirms the wide expression of spexin in normal human tissues. Our data also demonstrates that spexin is highly expressed among endocrine and epithelial tissues, which suggests the tissue-specific functional involvement. Circulating spexin appears to be inversely related to blood glucose and lipids in T2DM, which may represent an adaptation to the rise of glucose and lipid associated with T2DM. However, the exact physiological and/or pathophysiological role of spexin in endocrine diseases, particularly the effect of spexin on glucose and lipid metabolism, remains to be elucidated.
